CLVLY

Clinuvel Pharmaceuticals Limited [CLVLY] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CLVLY Stock Summary

Top 10 Correlated ETFs

CLVLY

Top 10 Correlated Stocks

CLVLY

In the News

CLVLY Financial details

Company Rating
-
Market Cap
490.24M
Income
56.55M
Revenue
151.67M
Book val./share
-
Cash/share
-
Dividend
0.03
Dividend %
0.2%
Employees
-
Optionable
No
Shortable
Yes
Earnings
28 Aug 2024
P/E
26.79
Forward P/E
-
PEG
1.56
P/S
10.13
P/B
4.98
P/C
-
P/FCF
22.11
Quick Ratio
7.02
Current Ratio
7.44
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
1.14
EPS next Y
-
EPS next Q
-
EPS this Y
47.62%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
10.29%
Revenue last 5Y
20.33%
Revenue Q/Q
-34.12%
EPS Q/Q
-43.59%
-
-
-
-
SMA20
-12.5%
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
16%
ROE
22%
ROC
0.26%
Gross Margin
90%
Oper. Margin
56%
Profit Margin
39%
Payout
6%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
8.54-13.97
52W High
-45.31%
52W Low
-11.13%
RSI
42
Rel Volume
0.02
Avg Volume
3.74K
Volume
90
Perf Week
-0.56%
Perf Month
-11.79%
Perf Quarter
5.18%
Perf Half Y
2.75%
-
-
-
-
Beta
0.744
-
-
Volatility
0.1%, 0.34%
Prev Close
0%
Price
7.11
Change
8.38%

CLVLY Financial Performance

CLVLY Dividend History

CLVLY Frequently Asked Questions

What is Clinuvel Pharmaceuticals Limited stock symbol ?

Clinuvel Pharmaceuticals Limited is a AU stock , located in Melbourne of Vic and trading under the symbol CLVLY

What is Clinuvel Pharmaceuticals Limited stock quote today ?

Clinuvel Pharmaceuticals Limited stock price is $7.11 today.

Is Clinuvel Pharmaceuticals Limited stock public?

Yes, Clinuvel Pharmaceuticals Limited is a publicly traded company.

Something similar

Top by Market Cap
AMZN
V
MSF.DE
META
MIX.JO
Top Correlated ETFs
CANE
ESUG.MI
GGLS
FIG
BZQ
Top Correlated Stocks
AQB
CYAD.BR
CNSP
TMG.L
SMTO3.SA
Similar Market Cap
0860.HK
CCO
0214.HK
1586.HK
SPKEP

Company Profile

Healthcare Biotechnology
  • Volume Average 3.74K
  • Market Capitalization 490.24M
  • CEO Dr. Philippe Jacques Wolgen M.B.A., M.D.
  • Headquarters Melbourne,VIC,AU
  • IPO Date 2008-01-30
  • Website https://www.clinuvel.com

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.